ADMA Biologics Inc (ADMA)

[mick]

$ADMA Revenue and Earnings Estimates (source: Seeking Alpha)

As you can see from Figure 5, ADMA’s P/S ratio drops to under a 3 for
every year after this one,
and ADMA’s P/E ratio off of future earnings estimates is well below the average of 15 for virtually every year after ADMA is projected to achieve profitability.


Even if you discounted these sales and earnings estimates by 10% per year as shown in Figure 6, these ratios would still suggest that ADMA is meaningfully undervalued.

Based on this valuation and commercial progress,
ADMA seems fairly de-risked under $3/share, but ADMA is also de-risked based on the fundamentals of plasma-based therapies in general.

IG is a great market to be in right now.

https://seekingalpha.com/article/4370328-adma-biologics-is-bargain-again-after-recent-sell-off